Literature DB >> 18308238

Trials in palliative treatment--have the goal posts been moved?

Peter Kirkbride1, Ian F Tannock.   

Abstract

Mesh：

Year:  2008        PMID： 18308238     DOI： 10.1016/S1470-2045(08)70041-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  12 in total

Review 1.  The value of progression-free survival to patients with advanced-stage cancer.

Authors:  Lesley J Fallowfield; Anne Fleissig
Journal:  Nat Rev Clin Oncol       Date:  2011-10-18       Impact factor: 66.675

Review 2.  A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment.

Authors:  Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

3.  Population-based trends in systemic therapy use and cost for cancer patients in the last year of life.

Authors:  R E Pataky; W Y Cheung; C de Oliveira; K E Bremner; K K W Chan; J S Hoch; M D Krahn; S J Peacock
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

4.  EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy.

Authors:  Amanda Caissie; Shaelyn Culleton; Janet Nguyen; Liying Zhang; Liang Zeng; Lori Holden; Kristopher Dennis; Esther Chan; Florencia Jon; May Tsao; Cyril Danjoux; Arjun Sahgal; Elizabeth Barnes; Kaitlin Koo; Edward Chow
Journal:  Support Care Cancer       Date:  2011-05-03       Impact factor: 3.603

5.  Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment.

Authors:  Kinsey Lam; Edward Chow; Liying Zhang; Erin Wong; Gillian Bedard; Alysa Fairchild; Vassilios Vassiliou; Mohamed Alm El-Din; Reynaldo Jesus-Garcia; Aswin Kumar; Fabien Forges; Ling-Ming Tseng; Ming-Feng Hou; Wei-Chu Chie; Andrew Bottomley
Journal:  Support Care Cancer       Date:  2013-06-19       Impact factor: 3.603

Review 6.  Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: a literature review.

Authors:  Ronald Chow; Nicholas Lao; Marko Popovic; Edward Chow; David Cella; Jennifer Beaumont; Henry Lam; Natalie Pulenzas; Gillian Bedard; Erin Wong; Carlo DeAngelis; Andrew Bottomley
Journal:  Support Care Cancer       Date:  2014-09       Impact factor: 3.603

Review 7.  Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Authors:  Linda Dirven; Jacob C Reijneveld; Neil K Aaronson; Andrew Bottomley; Bernard M J Uitdehaag; Martin J B Taphoorn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

8.  Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

Authors:  Karen A Autio; Antonia V Bennett; Xiaoyu Jia; Michael Fruscione; Tomasz M Beer; Daniel J George; Michael A Carducci; Christopher J Logothetis; Robert C Kane; Laura Sit; Lauren Rogak; Michael J Morris; Howard I Scher; Ethan M Basch
Journal:  J Oncol Pract       Date:  2013-06-25       Impact factor: 3.840

9.  Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran.

Authors:  Alireza Khoshnevisan; Mir Saeed Yekaninejad; Shahab Kamali Ardakani; Amir H Pakpour; Azam Mardani; Neil K Aaronson
Journal:  Health Qual Life Outcomes       Date:  2012-05-20       Impact factor: 3.186

Review 10.  The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations.

Authors:  Sarah King; Josephine Exley; Sarah Parks; Sarah Ball; Teresa Bienkowska-Gibbs; Calum MacLure; Emma Harte; Katherine Stewart; Jody Larkin; Andrew Bottomley; Sonja Marjanovic
Journal:  Qual Life Res       Date:  2016-04-02       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.